Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL phase 3 study of an intranasal live attenuated RSV vaccine in infants and toddlers
CTR20242605Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Oct 2024
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of RSVpreF vaccine in respiratory syncytial virus disease (RSV), sponsored by Sanofi. Started Oct 2024; status: terminated.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on CTR20242605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242605.